Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 October 2024 | Story Precious Shamase and Bulelwa Moikwathai | Photo Supplied
DHET international scholarship sessions 2024
Bulelwa Moikwaikwatlhai , Assistant Director: International Office and Dr Temwa Moyo, acting Director for International Scholarships at DHET.

The University of the Free State (UFS) Qwaqwa Campus recently hosted two information sessions on international scholarships, led by the Department of Higher Education and Training (DHET). These sessions were initiated by the Office for international Affairs.

In his welcoming address during the first information session for campus heads of department, Campus Vice-Principal: Support Services, Teboho Manchu, expressed his enthusiasm for the event and its potential benefits for students and staff. He emphasised the importance of these sessions in fostering growth and development. “We are looking forward to these engagements and hope that they will benefit all of us. Please feel welcome. I would also like to thank the Office for International Affairs and all the colleagues who have been working with them to make this interaction possible.”

Dr Temwa Moyo, acting Director for International Scholarships at the DHET, gave a comprehensive presentation on Erasmus+ programmes, which provide universities with opportunities and funding to collaborate on curriculum development for new programmes, capacity building in higher education, and full scholarships for joint master’s degrees, to name a few.

“The UFS has a significant international footprint, including on the African continent. Our department’s role is to stimulate international collaboration among institutions and to strengthen national collaborations to share best practices and build networks and capacity. This is the idea of the Erasmus + programmes,” explained Dr Moyo.

The DHET representative emphasised the department’s commitment to fostering international collaboration among universities and institutions. He explained that the Erasmus+ programmes aim to empower institutions and capacitate them to engage globally.

In the second student-centred session, Prof Ralph Clark, Director of the Afromontane Research Unit, encouraged students to take advantage of these opportunities because they enhance one’s networks, perspectives, and knowledge, as well as provide a platform for students to participate in and contribute to conversations and activities aimed at addressing global challenges with societal impact. The event provided attendees with various international opportunities through the DHET to support their academic pursuits. Students and staff learned about the benefits of studying abroad, the requirements, and the application process. The DHET’s emphasis on institutional partnerships also highlights the possibility of enriching academic exchange and cultural experiences.

Overall, the DHET international scholarship sessions on the UFS Qwaqwa Campus were a resounding success, with both students and staff attending in numbers. These sessions inspired students and staff to explore the exciting possibilities of global engagements.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept